INVITATION

Dear Colleagues,

It is with great regret that we have decided to host a hybrid congress of 1st Annual Meeting of the Brazil-Russia-India-China-South Africa IBD Consortium (BRICS IBD 2021) due to the COVID-19 pandemic. We have changed the agenda accordingly. BRICS IBD 2021 will be held virtually and on-site from Nov. 18-20, 2021. As we prioritize participants' safety and health, this difficult decision has been made to ensure a safe congress.

The Governing Board of BRICS IBD Consortium is delighted to host this international meeting of the latest update in IBD. This meeting will provide a support network for IBD specialists in Brazil, Russia, India, China and South Africa on clinical and basic research together with communication through online and entitative resources. The aims of this meeting are to exchange experience and knowledge of in inflammatory bowel diseases with specialists in developed areas, and to provide a truly global perspective and an opportunity for clinicians and researchers from BRICS countries to present their research and interact with participants over the world. There will also be excellent opportunities for clinicians and researchers to get up-to-date information and education with the diagnosis and management of inflammatory bowel disease at the exciting meeting and multiple workshops.

The theme of BRICS IBD 2021 "Horizon of Inflammatory Bowel Disease in BRICS" encourages all participants sharing their latest clinical experiences and basic opinions in inflammatory bowel disease. We sincerely hope that you will show in the virtual congress BRICS IBD 2021. Your presence will be a truly worthwhile experience. Undoubtedly, the success of the BRICS IBD 2021 is due to the enthusiasm and generosity of the scientists and clinicians who attend. We therefore encourage you to participate and contribute to this amazing success.

We look forward to seeing you all.

Yours sincerely,

Zhihua Ran President

Thibwa Ran

Kaichun Wu **Congress President**

aich_(llu

The Brazil-Russia-India-China-South Africa IBD Consortium **BRICS 2021**







Senior Speakers

Jean-Frederic Colombel



Icahn School of Medicine at Mount Sinai 1470 Madison Avenue 10029 NY New York United States of America Email:

Claudio Fiocchi



NC2-120 Lerner Research Institute, 9500 Euclid Avenue, Cleveland, Ohio 44195 E-mail:

Silvio Danese



Humanitas University IBD Center 20089 Rozzano, Milan Italy Email:

David Rubin



Director, Inflammatory Bowel Disease Center University of Chicago Medical Cente IL 60637 MC4076 Illinois Chicago Email:





Senior Speakers

Charlie Lees



Western General Hospital Crewe Road South Edinburgh, Edinburgh EH4 2XU United Kingdom charlie.lees@ed.ac.uk

Gilaad Kaplan



Snyder Institute for Chronic Diseases & Institute of Public Health
Departments of Medicine & Community Health
Sciences
TRW 6D56, 3280 Hospital Drive NW
Calgary, AB T2N 4Z6, Canada
Email:







J7:00 – 21:00	– 21:00 Registration	
08:00 – 11:30	BRICS Board Meeting	
Time	Virtual Room 1	Virtual Room 2
	BRICS Satellite Forum (by Abbvie) Clinical decision support for Crohn's disease Chair: Zhihua RAN (China)	
13:25 – 13:30	Vineet AHUJA (India) Welcome Zhihua RAN (China)	
13:30 – 13:50	Individualized management of CD: heterogeneity of disease Yao HE (China)	
13:50 – 14:10	Tight control of biologics: what indicators shall we focus on Jean-Frederic COLOMBEL (USA)	
14:10 – 14:30	Biologics in combination with thiopurines: when and how? Ajit SOOD (India)	
14:30 – 14:50	Medical and surgical management of perianal Crohn's disease Xiaoqi ZHANG (China)	
14:50 – 15:10	Optimizing perioperative management in CD surgery Weiming ZHU (China)	
15:10 – 15:30	Pathways beyond anti-TNFs, JAK pathways and other for biologics Claudio FIOCCHI (USA)	
15:30 – 15:35	Closing Remarks Vineet AHUJA (India)	







RICS Satellite Forum (by Janssen)		
	Challenge Cases	
ovel therapeutic targets for IBD		Chair: Qian CAO (China)
Chair: Kaichun WU (China)		Fangyu WANG (China)
Gillian WATERMEYER (South Africa)		Panel discussion:
		Feng TIAN (China)
		Min ZHI (China)
		Jin LI (China)
		Yiqun HU(China)
/elcome	Welcome	
Kaichun WU (China)		Fangyu WANG (China)
efine the quality of IBD center: what	Case I	
		Xianrui WU (China)
	Case II	
		Yubei GU (China)
	Case III	A4: 0154 (61:)
		Min CHEN (China)
, ,	Casa IV	
_	Case IV	Armon VARDANVAN (Bussia)
• •		Armen VARDANYAN (Russia)
	Case V	
•	Case v	Saurabh KEDIA (India)
·		Suurubii KEDIA (iliulu)
	Case VI	
, , ,	Cube VI	Adam BOUTALL (South Africa)
	Closing Remarks	The state of the s
		Qian CAO (China)
/ en tie	Chair: Kaichun WU (China) Gillian WATERMEYER (South Africa) elcome Kaichun WU (China)	Chair: Kaichun WU (China) Gillian WATERMEYER (South Africa) Welcome Kaichun WU (China) Iffine the quality of IBD center: what ould we do? Minhu CHEN (China) Iture targets for biologics in mucosal ralling of Crohn's disease Charlie LEES (UK) Inderstanding treat-to-target and how can reget Marina SHAPINA (Russia) Dologics for ulcerative colitis – stratification rapplication? Yufang WANG (China) Ility of ERAS after inflammatory bowel sease operations Ping LAN (China) Down do we sequence biologic therapies? Gillian WATERMEYER (South Africa) Dosing Remarks Case VI Closing Remarks







07:00 – 21:00	Registration
---------------	--------------

Time	Virtual Room 1	Virtual Room 2
08:20 - 08:30	Opening Ceremony	
	Zhihua RAN (China)	
	Kaichun WU (China)	
	Clinical Forum I	BRICS Debates
	Ulcerative colitis treatment: an insight into	Chair: Claudio FIOCCHI (USA)
	daily clinical practice	Flavio STEINWURZ (Brazil)
	Chair: Minhu CHEN (China)	Yingde Wang (China)
	Yunsheng YANG (China)	
08:30 - 08:50	Novel potential biomarkers for the	08:30 - 08:45 Combined two biologics when
	diagnosis and monitoring ulcerative colitis	resources are sufficient
	Kaichun WU (China)	Yuqi QIAO (China)
08:50 - 09:10	Four stages of inflammatory bowel diseases	08:45 – 09:00 No need for the combination of two
	Gilaad KAPLAN (Canada)	biologics
		Genoile SANTANA (Brazil)
		09:00 – 09:15 Maintain biologics when low through
		level
09:10 - 09:30	Evolving concepts in ulcerative management	Rogerio Saad HOSSNE (Brazil)
	Silvio DANESE (Italy)	09:15 – 09:30 Shift to immnosuppresants when low
		through level
		Lingna YE (China)
		09:30 – 09:45 B1 phenotype in CD: which biologic
09:30 – 09:45	Best Abstract I	agent may be prior
09:45 – 10:00	Best Abstract II	Marta MACHADO (Brazil)
05.45 10.00	Dest Abstract II	09:45 – 10:00 B1 phenotype in CD: equal choice for
		each biologic agent
		Fang XIAO (China)

10:00 – 10:30	Coffee Break	







Time	Virtual Room 1	Virtual Room 2
	Clinical Forum II	Basic Forum
	Optimize treatment and disease activity	Translational markers from bench to bedside
	monitoring of CD	Chair: Weiguo DONG (China)
	Chair: Jiaming QIAN (China)	Yulan LIU (China)
	Yanqing LI (China)	Chenggong YU (China)
	Zhihua RAN (China)	
10:30 – 10:50	Dilemma for curing perianal Crohn's Disease	Manipulating resident microbiota to enhance
	Zhihua RAN (China)	regulatory immune function for IBD
		Rakesh KOCHHAR (India)
10:50 – 11:10	Is proactive TDM a pseudo-proposition for	The fundamental for intestinal fibrosis
	Crohn's disease?	Ren MAO (China)
	Charlie LEES (UK)	
11:10 – 11:30	What can we learn from SECURE-IBD?	Long noncoding RNAs involved in the pathogenesis of
	David RUBIN (USA)	IBD
		Zhanju LIU (China)
11:30 – 11:45	Best Abstract III	Best Abstract V
11:45 – 12:00	Best Abstract IV	Best Abstract VI
Time	Virtual Room 1	Virtual Room 2
	Lunch Symposium (by Takeda)	Lunch Symposium (by Janssen)
	Optimize management of IBD: from	Biological therapies: from the initial to the future
	emerging evidence to clinical practice	Chair: Minhu CHEN (China)
	Chair: Jiaming QIAN (China) Kaichun WU (China)	Huahong WANG (China)
	Kalchali Wo (China)	
12:00 – 12:25	Targeting progression of IBD to improve	Monitoring of anti-TNF antibody: when and how to
	patient outcomes	handle
	Zhihua RAN (China)	David RUBIN (USA)
12:25 – 12:50	Early intervention optimizes UC patients'	Pathways beyond anti-TNFs, IL pathways and other
	outcomes	for biologics
	Yan CHEN (China)	Charlie LEES (UK)
12:50 – 13:15	An evidence-based approach to changing	Can histological healing be achieved in CD?
	clinical course in CD	Jean-Frederic COLOMBEL (USA)







Time	Virtual Room 1	Virtual Room 2
	BRICS Forum I	Young Investigator & Education Forum
	IBD TB issues in BRICS and the West	Evaluation and traditional intervention in IBD
	Chair: Pinjin HU (China)	Chair: Yufang WANG (China)
	Ying HAN (China)	Xiang GAO (China)
	Yao HE (China)	Lu XIA (China)
13:30 – 13:50	Concomitant infection differences in developing and developed areas	Use of antidepressants in the treatment of depression with IBD
	Hong YANG (China)	Gilaad KAPLAN (Canada)
13:50 – 14:10	Monitoring and managing IBD associated TB:	Exploring endoscopic therapy for Crohn's disease
	the practice in India	strictureplasty
	Vineet AHUJA (India)	Yan ZHANG (China)
14:10 – 14:30	Monitoring and managing IBD associated TB:	Benefit and complications for capsule endoscopy for
	the practice in Brazil	IBD
	Genoile SANTANA (Brazil)	Yue LI (China)
14:30 – 14:50	Monitoring and managing IBD associated TB:	Does 5-ASA really useless for Crohn's disease (by
	the practice in Russia	CMS)
	Diana ABDULGANIEVA (Russia)	Jie LIANG (China)
14:50 – 15:10	Monitoring and managing IBD associated TB:	From mucosal healing to histologic healing in
	the practice in China	ulcerative colitis
	Qian CAO (China)	Jun SHEN (China)
15:10 – 15:30	Monitoring and managing IBD associated TB:	Treatment of pediatric Crohn's disease: what should
	the practice in South Africa	differ from adults
	Adam MAHAMED (South Africa)	Ying HUANG (China)

15:30 – 15:50 Coffee Break





Time	Virtual Room 1
	BRICS Forum II
	Clinical decision support for IBD
	Chair: Marina SHAPINA (Russia)
	Qing ZHENG (China)
	Changing Zheng (China)
15:50 – 16:10	Mercaptopurine concentration monitoring and adverse events prediction for IBD
	Xiang GAO (China)
16:10 – 16:30	Thalidomide as second-line therapy for CD: from mechanism to effectiveness
	Mashiko SETSHEDI (South Africa)
16:30 – 16:50	Pathogenic and therapeutic role of the Microbiome
	Heitor SOUZA (Brazil)
16:50 – 17:10	Choosing strategy in IBD when steroids have failed
	Irina GUBONINA (Russia)
Time	Virtual Room 1
	Next Target of IBD for BRICS
	Chair: Zhihua RAN (China)
	Kaichun WU (China)
17:10 – 17:16	Next Target of IBD in BRICS – establish a smooth connection within BRICS
17.10	Elena BELOUSOVA (Russia)
17:16 – 17:22	Next Target of IBD in BRICS – communication with other organizations
17.10 17.22	David EPSTEIN (South Africa)
17:22 – 17:28	Next Target of IBD in BRICS – how to set up standardized medical treatment
17.22 17.20	Flavio STEINWURZ (Brazil)
17:28 – 17:34	Next Target of IBD in BRICS – optimize surgical treatment
17.20 - 17.34	
17:34 – 17:40	Weiming ZHU (China) Next Target of IBD in BRICS – from bench to translation
17.54 - 17.40	
17.40 17.55	Govind MAKHARIA (India)
17:40 – 17:55	Panel discussion
	Elena BELOUSOVA (Russia) Minhu CHEN (China)
	David EPSTEIN (South Africa) Kaichun WU (China)
	Govind MAKHARIA (India) Zhihua RAN (China)
T'	Vinteral Barrers 4
Time	Virtual Room 1
17:55 – 18:00	Closing Remarks
	Kaichun WU (China)
	Zhihua RAN (China)







CONTACT US

BRICS IBD Consortium Secretary

Add: 160 # Pu Jian Road, Shanghai, China, 200127

Tel: +86 21 58752345

Fax: +86 21 58394262

Email: secretariat@bricsibd.org



